SULINNO®: Adalimumab Injection
Products
Information
Received NMPA marketing approval on August, 2020
Approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, and polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, non-infectious uveitis.
A total of eight approved indications have been included in the NRDL